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Xmay be most cost-effective in these higher-risk categories,
again because the prevalence will be higher and costs
associated with renal failure potentially avoided if
clinical action can be undertaken to prevent further renal
deterioration and eliminate the need for dialysis.
Finally, our composite risk score and guide may have
utility in informing patients and their families about OHT
and its associated risks. More specifically, the guide in
Table 3 can be used to give a realistic impression of what
the risks are of needing dialysis at least temporarily in the
postoperative period. Although our score is a predictor of
acute renal failure and not necessarily the need for chronic
dialysis, the former is certainly a risk factor for the latter. In
a future study, it may be important to evaluate the specific
rates of chronic dialysis stratified by acute renal failure
risk category, because ongoing dialysis would certainly
affect a patient’s quality of life and may therefore be
important to disclose in the consenting process.
Study Limitations
An important limitation of our study is that other
variables that may affect rates of renal failure are not
available in the UNOS database and therefore are unable
to be included in our risk index. These variables include
the use of nephrotoxic medications, perioperative fluid
balance, intraoperative and postoperative bleeding, and
episodes of perioperative hypotension, to name a few. In
addition, the decision to dialyze a patient can vary between
providers and between institutions. There is a possibility
that a patient who was categorized as having renal failure
requiring dialysis in our study may not have been dialyzed
with a different provider or at a different institution.
Another limitation is that our analysis was confined to the
postoperative period, but there is a possibility that an
OHT recipient may have been readmitted after hospital
discharge and subsequently dialyzed. Finally, our analysis
is limited to renal failure requiring dialysis and did not
evaluate less severe forms of acute kidney injury, because
these data are not available in the UNOS registry.
CONCLUSIONS
This study derived and validated a composite risk index
for postoperative acute renal failure requiring dialysis after
OHT using data from 14,635 patients. The risk score was
then used to construct a simple clinical guide to provide cli-
nicians the ability to prospectively estimate postoperative
renal failure risk in OHT recipients. The risk index and
clinical guide may have potential applications in guiding
the perioperative management of OHT recipients and in
clinical research stratification. Because postoperative acute
renal failure is a powerful predictor of mortality, other
morbidity, and resource use, continued improvement in
preventing its occurrence and optimizing its management
is essential.1104 The Journal of Thoracic and Cardiovascular SurReferences
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Dr Mark Slaughter (Louisville, Ky). In the preoperative vari-
ables that were evaluated, it appears as though transpulmonary
gradient and pulmonary vascular resistance were not included.
These can affect donor right ventricular function and lead to
low-flow output situations and poor renal perfusion. Were these
variables not available, and what influence would they have on
the risk score if included?
Dr Kilic. Some hemodynamic variables are inconsistently
recorded in the UNOS database. Those variables that had more
than 20% missing data were excluded as potential risk factors in
our score calculation. Other hemodynamic variables did not
meet entry criteria for our multivariable model. The other item
with the hemodynamic parameters is exactly when they’re being
measured. In the UNOS database, they are measured as close togery c September 2014
Kilic et al Cardiothoracic Transplantation and Mechanical Circulatory Supportthe heart transplantation as possible, which I think is a reliable
measure. However, again because of the high percentage of
missing data or the lack of predictive power, those variables
were excluded.
Dr Slaughter. Similarly, for preoperative variables, I’m
surprised that status 1A and 1B were not included. You would
think a higher-risk individual might be at higher risk for renal
failure.
Dr Kilic. We looked at each component of what would
determine a patient to be UNOS status 1 or 2. So bridging with
ventricular assist devices, extracorporeal membrane oxygenation,
patients on inotropes, all those variables were looked at and
evaluated in the analysis. Some of those variables were significant
in univariate analysis; however, after our statistical methodology,
they did not meet inclusion criteria for the final multivariable
model.
Dr Slaughter. Although mentioned as limitations, operative
events that result in bleeding, transfusion, hypotension, and
decreased donor organ function will significantly affect post-
operative renal function. Do you think your risk score is just a
surrogate marker for those patients who will not tolerate
perioperative complications?
Dr Kilic. That’s an excellent point, and it is something we can’t
control for because those variables are not present in the UNOS
database. So it’s difficult to tell. It may very well be a surrogate.
Dr Slaughter. The concern would be if you have a patient with
a predicted 20% risk. The question is, are you going to exclude that
patient? But if you have a perfect operation, once again, the odds
are the patient probably will be okay.
Last, along these lines, will the risk score change your approach
to managing patients? An example is a patient with decreased renal
function, diabetes, and age more than 60 years, thus a high-risk
patient for post-transplant renal failure; should that patient
automatically get a ventricular assist device to demonstrate
improvement in renal function before receiving a transplant that
might lead to better organ allocation?
Dr Kilic. That’s one of the potential applications of this risk
score. Other applications would be looking at induction therapy,
for instance. Approximately 50% of transplant recipients receive
induction therapy, and it would be interesting to look at those
patients who are at very high risk for renal failure preoperatively
whether or not induction therapy would be more useful or not.
These are all potential clinical applications and certainly deserve
more attention.
Dr Robert Higgins (Columbus, Ohio). Yes, I agree, Dr Kilic, a
very articulate description of a complicated issue. I guess the ques-
tion I had in this risk-adverse world, knowing that we are trying to
optimize outcomes for these heart transplant recipients, is should
we now use this tool as a discriminator of patients who are at
risk for renal failure in the perioperative period? Can creatinineThe Journal of Thoracic and Carclearance less than 30 be a marker for impending renal failure
postoperatively? Maybe they shouldn’t even be considered for
heart transplant alone but rather heart-kidney transplantation,
which would then allow you to mitigate the effects of whatever
risk factors or variables are being played out here.
Dr Kilic. When we’re talking about patient selection, which
patients should undergo heart transplantation, we should focus
on models that are looking at postoperative or 1-year mortality
risk. Renal failure is a strong predictor for mortality, but there
are other components that certainly contribute to overall mortality
risk.
The utility of this score is to specifically tailor certain aspects of
postoperative management and in terms of clinical research strat-
ification. In terms of being a score that we look at for determining
patient selection, again, I think models that are aimed at measuring
risk of overall mortality are the models we should look at for that.
Dr Higgins.Yes, this may be a tool that would be effective for a
lot of people.
Dr Thoralf Sundt (Boston, Mass). My question relates to hav-
ing sat for many hours in transplant selection conferences
agonizing over whether the patient ought to have a heart or a
heart-kidney. How many times have we had that discussion? The
cardiologist or nephrologist says, ‘‘Oh, the kidneys will get bet-
ter,’’ and sometimes you say it too.
Are you able to look within your own institutional database at
those patients who had dodgy renal function preoperatively and
separate those who did or did not get better and use this score to
distinguish them? Is this actually applicable to the related
question, will somebody with preoperative renal failure get better
after a transplant or not?
Dr Kilic. Yes. Again, unfortunately, the UNOS database is
limited in terms of the amount of postoperative data it has. Renal
failure is simply coded as whether it’s present or not, and that’s
only in cases where dialysis is needed. But I agree, looking at a
single institution series where you have more clinical data
available, including postoperative creatinine levels and other
markers of renal failure, would be very interesting.
Dr Sundt. That’s where you’d need to do it, in your own
database. Thanks.
Dr Glenn Whitman (Baltimore, Md). We too suffer every
Tuesday afternoon with the dilemma of doing an isolated heart
transplant versus a dual-organ transplant, pulling the kidney with
the heart. Or, if we do not do a dual transplant, should we oversize
because of worry about right ventricular failure, elevated central
venous pressure, and postoperative renal function. But we can’t
do that study Dr Sundt just mentioned because we already use in-
duction therapy selectively in patients who we think are going to
have a high risk of renal insufficiency. Induction therapy is expen-
sive, so we do not use it uniformly, but when someone is at high
risk, we use it.diovascular Surgery c Volume 148, Number 3 1105
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